ZNF185

Across TCGA pan-cancer cohorts, ZNF185 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF185 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ZNF185 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF185 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

OV, LIHC, and CESC are the cancer types where ZNF185 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.195	0.541	.015	18	view →
LIHC	OS	Median	II,III,IV	0.010	0.697	<.001	12	view →
CESC	DFS	Median	II,III,IV	0.193	0.705	.045	6	view →
LUSC	OS	Median	All	0.231	0.662	.008	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.336	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF185–OV (DFS)

Open the OV breakdown →